Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

NCT04534439 is registered in ClinicalTrials.gov with Aptabio Therapeutics, Inc. as lead sponsor.

NCT NCT04534439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04534439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
Lead sponsor
Aptabio Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 24, 2020
Completion date
August 23, 2021
Enrollment
140 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, diabetic nephropathies, nephropathy, diabetic